Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study To Evaluate The Use Of Autologous T- Antigen-Presenting Cells (T-APC) To Enhance The Persistence Of Adoptively Transferred CD8+ Antigen-Specific T Cell Clones (CTL) Following Cyclophosphamide Conditioning For Patients With Metastatic Melanoma.

Next Previous
Trial Profile

Phase I Study To Evaluate The Use Of Autologous T- Antigen-Presenting Cells (T-APC) To Enhance The Persistence Of Adoptively Transferred CD8+ Antigen-Specific T Cell Clones (CTL) Following Cyclophosphamide Conditioning For Patients With Metastatic Melanoma.

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Aldesleukin; Melanoma vaccine; T cell replacement therapy
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacodynamics

Most Recent Events

  • 21 Apr 2014 Biomarkers information updated
  • 20 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
  • 05 Mar 2012 Planned End Date changed from 1 Jan 2013 to 1 May 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top